Edition:
India

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

170.40USD
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
$170.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,710
52-wk High
$182.12
52-wk Low
$90.20

Latest Key Developments (Source: Significant Developments)

GW Pharmaceuticals Plc Reports Q4 Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - GW Pharmaceuticals PLC ::REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR THE QUARTER ENDED DECEMBER 31, 2018.Q4 REVENUE $6.7 MILLION VERSUS $4.0 MILLION.MOVES TO A NEW FISCAL YEAR-END BEGINNING JANUARY 1, 2019.EPIDIOLEX U.S. LAUNCH PROGRESSING TO PLAN.QTRLY LOSS PER SHARE $0.20.  Full Article

GW Pharmaceuticals PLC Files For Potential Mixed Shelf Offering; Size Not Disclosed
Saturday, 19 Jan 2019 

Jan 18 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

GW Pharmaceuticals PLC Reports Fiscal Fourth Quarter Results
Wednesday, 28 Nov 2018 

Nov 27 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC REPORTS FISCAL FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.GW PHARMACEUTICALS PLC - QTRLY LOSS PER SHARE $0.23.GW PHARMACEUTICALS PLC QTRLY TOTAL REVENUES $2.4 MILLION VERSUS $2.5 MILLION.GW PHARMACEUTICALS PLC - CASH AND CASH EQUIVALENTS AT SEPTEMBER 30, 2018 WERE $354.9 MILLION COMPARED TO $322.2 MILLION AS OF SEPTEMBER 30, 2017.  Full Article

GW Pharma Says DEA Has Rescheduled Epidiolex Oral Solution To Schedule V
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC AND ITS U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCE THE DEA HAS RESCHEDULED EPIDIOLEX® (CANNABIDIOL) ORAL SOLUTION TO SCHEDULE V.GW PHARMACEUTICALS PLC - WITH DEA DECISION, PRODUCT LABEL FOR EPIDIOLEX WILL BE FINALIZED.GW PHARMACEUTICALS PLC - ANTICIPATES MAKING EPIDIOLEX AVAILABLE WITHIN NEXT SIX WEEKS.GW PHARMACEUTICALS PLC - MEDICINE WILL BE MARKETED IN UNITED STATES BY GREENWICH BIOSCIENCES.  Full Article

GW Pharmaceuticals Reports Fiscal Q3 Results
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC REPORTS FISCAL THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.  Full Article

FDA Approves Epidiolex (Cannabidiol) Oral Solution To Treat Rare, Severe Forms Of Epilepsy
Monday, 25 Jun 2018 

June 25 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION FOR TREATMENT OF SEIZURES ASSOCIATED WITH 2 SEVERE FORMS OF EPILEPSY IN PATIENTS 2 YRS & OLDER.U.S. FDA - FDA GRANTED APPROVAL OF EPIDIOLEX TO GW RESEARCH LTD.U.S. FDA - EPIDIOLEX APPROVED FOR TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME IN PATIENTS 2 YRS & OLDER.  Full Article

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - GW Pharmaceuticals Plc ::GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S..GW PHARMACEUTICALS - NOW REACQUIRED FULL OWNERSHIP OF DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT IN U.S. WITHOUT UPFRONT PAYMENT TO OTSUKA​.GW PHARMACEUTICALS - ‍AGREED TO MAKE CONTINGENT MILESTONE PAYMENTS TO OTSUKA, FIRST OF WHICH WOULD BECOME DUE UPON FDA APPROVAL OF SATIVEX​.GW PHARMACEUTICALS PLC - ‍TERMINATION OF PREVIOUS LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO IN RELATION TO SATIVEX IN U.S.​.  Full Article

GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
Wednesday, 6 Dec 2017 

Dec 5 (Reuters) - Gw Pharmaceuticals Plc ::GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.GW PHARMACEUTICALS PLC - INTENDS TO SELL $225 MILLION OF AMERICAN DEPOSITARY SHARES.  Full Article

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.